
Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors ...
Introduction Psoriasis is a chronic inflammatory skin disease affecting approximately 2–3% of the global population,1 significantly impacting patients’ quality of life. Over time several biological therapies have emerged as promising treatment options, …